getting the best treatment to the most people possible n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Getting the best treatment to the most people possible PowerPoint Presentation
Download Presentation
Getting the best treatment to the most people possible

Loading in 2 Seconds...

play fullscreen
1 / 14

Getting the best treatment to the most people possible - PowerPoint PPT Presentation


  • 53 Views
  • Uploaded on

Getting the best treatment to the most people possible. Enabling policies: threats & opportunities MSF Access Campaign. Funding crisis . Impact on rt to health - not universal but rationed Impact on second-line and reluctance to bring in newer (better) treatment into first line

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Getting the best treatment to the most people possible' - knoton


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
getting the best treatment to the most people possible

Getting the best treatment to the most people possible

Enabling policies: threats & opportunities

MSF Access Campaign

funding crisis
Funding crisis
  • Impact on rt to health - not universal but rationed
  • Impact on second-line and reluctance to bring in newer (better) treatment into first line
  • Starting with TDF but going forward with integrase

inhibitors

  • Particularly acute for middle income countries
  • Danger of losing community monitoring
  • Funding crisis for organisations who work on IP barriers
slide3

Neglected co-infectionsAmong patients with AIDS, chronic HCV infection is associated with a 50% increase in mortality Hepatitis treatment for co-infected patientsReluctance to treat, price and regulatory issues

slide4
WTO

Middle income countries

Low income countries

Big issue of 2016

implementation deadline for

product patents

LDCs to introduce product

patents, need for extension

NOT COUNTRY BY COUNTRY

BUT ALL LDCs

Issue of OAP and ARIPO just

registering patents even before

deadline

Fencing in middle income

developing countries

Mis-use (ever-greening to obtain

patents on older patents in MICs

Less freedom to operate for

generics undermines production

Access – treatment available in

LDCs not available in MICs

e g linezolid patent in sa
e.g. Linezolid patent in SA

R676 per tablet in private sector (MSF price); R264

per tablet in public sector (available for R9.9 from

Cipla)

MSF wanting to use for patients failing DR-TB

Up to R108,000 per patient (6 months)

Basic patent until 2014; crystalized form II

patent until 2022 (will block entry?)

ever greening rejections due to local examination and application of strict patentability criteria
Ever-greening Rejections due to local examination and application of strict patentability criteria

Credit for this particular slide: Lawyers Collective HIV/AIDS Unit, India

novartis
NOVARTIS

Novartis DROP the case kick off the campaign – protests timed with the court hearings to maintain public attention.

slide8

Growing movement – SA, Thailand, Argentina, Philippines - Examination system weeds out patent applications that should not be granted. Direct benefit with earlier expiry of patents on ARVs.

Compulsory licensing

China - key announcement of procedures

India – applications by generic competitors

South Africa – reforms needed

us and eu fta negotiations expanding and now reaching a very crucial stage
US and EU FTA negotiations expanding and now reaching a very crucial stage

2nd Udyog Bhavan protest Oct 2010: Comment posted "I have never seen so many police people with batons and guns.“

http://www.bbc.co.uk/news/health-11488711

vls threats or opportunities creating generic monopolies
VLs Threats or Opportunities“Creating generic monopolies”
  • New business model – exclude middle income countries
  • Do we know enough – secret deals
  • Shrinking access even for Indian patients
  • Conditions that block API (raw materials) access
  • Undermine CLs
  • Generics have to keep out of markets where there are no patent barriers
  • Venezuela: no patents granted, only applications filed.

BILATERAL DEALS GETTING WORSE.

what we can do
What we can do
  • Start Hep C treatment in some countries
  • Getting educated on new drugs
  • Patent oppositions on new drugs to prevent

long monopolies

- CLs needed for MICs

- Defend India’s law

- SA ‘Fix the Patent Law’ Campaign crucial

- STOP the FTAs

- VLs cannot be ignored